Related Experiment Video
Updated: Oct 19, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
[COVID-19-induced coagulopathy and thrombosis manifestations]
O Sedlaczek1,2, W Wagner3,4, C E Dempfle5
1Radiology Cooperation Uni/DKFZ, Division of Radiology, NCT, Im Neuenheimer Feld 460, 69120, Heidelberg, Deutschland. o.sedlaczek@med.uni-heidelberg.de.
Insights
COVID-19 (coronavirus disease 2019) is a systemic disease causing hypercoagulability. Low molecular weight heparins are indicated for hospitalized patients, with radiology crucial for diagnosis and prevention.
Area of Science:
- Vascular Medicine
- Infectious Diseases
- Radiology
Background:
- COVID-19 (coronavirus disease 2019) presents as a systemic disease with multiorgan involvement.
- A hypercoagulable state, manifesting as vasculopathy, is a key characteristic of COVID-19.
- Microstructural vascular changes and diffuse perfusion disorders are significant findings.
Purpose of the Study:
- To highlight the role of hypercoagulability and vasculopathy in COVID-19.
- To emphasize the importance of radiological diagnostics in identifying vascular changes.
- To discuss therapeutic interventions for COVID-19-associated thrombosis.
Main Methods:
- Radiological diagnosis to identify macrovascular and microvascular pathologies.
- Assessment of regional hypoperfusion in various organ systems, including the lungs.
- Review of evidence for antiplatelet drugs and heparins.
Main Results:
- Radiological findings include macrovascular pathologies and diffuse perfusion disorders.
- Regional hypoperfusion is detectable in the lungs, with or without pulmonary embolism.
- Similar vascular findings are observed across multiple organ systems.
Conclusions:
- Therapeutic intervention with low molecular weight heparins is indicated for hospitalized COVID-19 patients.
- Extended radiological diagnostics are essential for detecting micro- and macrovascular thrombosis.
- Radiological findings form the basis for adapted therapy and secondary prevention strategies.
Clinical Issue:
Clinically, COVID-19 (coronavirus disease 2019) is increasingly seen as a systemic disease associated with multiorgan involvement through a hypercoagulatory condition in the sense of vasculopathy.
Standard Treatment:
Treatment with antiplatelet drugs or heparins appears to be indicated. The current evidence, at least for acetylsalicylic acid (ASA), is lacking.
Diagnostic Work-Up:
Corresponding to the significant proportion of primarily microstructural vascular changes, the radiological diagnosis showed not only macrovascular pathologies, but also diffuse perfusion disorders.
Performance:
Regional hypoperfusion in the lungs can be detected with and without pulmonary arterial embolism. Similar findings can be found in almost all organ systems.
Practical Recommendations:
A therapeutic intervention using low molecular weight heparins in hospitalized patients in situation-adapted dosage is indicated and is discussed in detail. In the detection of micro- and macrovascular thrombosis in the context of COVID-19, extended radiological diagnostics play a central role and are the basis of adapted therapy and secondary prevention.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis I: Introduction
Endocarditis II: Clinical Features of Infective Endocarditis
Venous Thrombosis III: Interprofessional Care

